

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

PROPOSED PURCHASE OF LIABILITY INSURANCE FOR THE COMPANY AND ITS DIRECTORS, SUPERVISORS AND SENIOR MANAGEMENT

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

To further enhance the Company's corporate governance and risk management system, facilitate the due exercise of powers and the effective discharge of duties by the Company's directors, supervisors and senior management, foster a sound environment for the sustainable development of the Company, and safeguard the legitimate rights and interests of the Company and its shareholders, the Company proposes to purchase liability insurance (the “**Liability Insurance**”) for the Company and all of its directors, supervisors and senior management (the “**Proposed Purchase of Liability Insurance**”) in accordance with applicable laws, regulations and rules, including the *Company Law of the PRC* (《中华人民共和国公司法》), the *Code of Corporate Governance of Listed Companies* (《上市公司治理准则》) issued by the China Securities Regulatory Commission (中国证券监督管理委员会).

On 13 August 2025, the Company convened its 5th Board meeting for the financial year ending 31 December 2025 (“**FY2025**”), during which the Board considered, amongst others, the resolution in relation to the Proposed Purchase of Liability Insurance. All the directors of the Company (the “**Directors**”) will be insured under the Liability Insurance and are therefore regarded as interested in the Proposed Purchase of Liability Insurance. Accordingly, they have abstained from voting on the resolution in relation to the Proposed Purchase of Liability Insurance, and the Board resolved that the said resolution be approved for submission to shareholders for consideration and approval at a general meeting of the Company to be convened in due course.

The details of the Proposed Purchase of Liability Insurance are set out below.

1. OVERVIEW OF THE PROPOSED LIABILITY INSURANCE PLAN

Policyholder	: The Company
Insured	: The Company and/or all of its Directors, supervisors, senior management personnel, and employees with managerial responsibilities
Limit of Liability	: Not exceeding RMB100 million (subject to the insurance contract as finally executed)
Premium	: RMB250,000 per annum (subject to the insurance contract as finally executed)

Policy Period : One (1) year (with the exact commencement and expiry dates subject to the insurance contract as finally executed; renewable or subject to re-purchase annually thereafter)

2. AUTHORISATION MATTERS

In order to improve decision-making efficiency, the Board proposes to seek shareholders' approval to authorise the management of the Company to handle all matters relating to the purchase of the Liability Insurance within the framework of the proposed insurance plan. Such matters include, but are not limited to, selecting the insurance provider, determining the insured liability limit, negotiating the insurance terms, executing the relevant legal documents, attending to other matters in connection with the purchase of the Liability Insurance, as well as arranging its renewal or re-purchase upon or prior to the expiry of the insurance contract.

3. DECISION-MAKING PROCEDURES

The Board, at its 5th meeting for FY2025, considered the resolution in relation to the Proposed Purchase of Liability Insurance.

As all the Directors will be insured under the Liability Insurance and are therefore regarded as interested in the Proposed Purchase of Liability Insurance, they have abstained from voting on the resolution in relation to the Proposed Purchase of Liability Insurance. The Board resolved that the said resolution be approved for submission to shareholders for consideration and approval at a general meeting of the Company to be convened in due course.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
14 August 2025